ReviewFrontiers in pharmacology2026
The mechanisms and therapeutic advances of interactions between breast cancer and cardiovascular diseases.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Currently, breast cancer (BC) and cardiovascular diseases (CVD), as two major diseases that seriously threaten global public health, have become major public health problems that need to be urgently solved as their morbidity and mortality rates continue to rise. In recent years, with the continuous improvement of BC diagnosis and treatment, the overall survival of patients has been significantly prolonged, but CVD has gradually become one of the major non-oncological causes of death among BC survivors. It has been pointed out that there are multiple common mechanisms between BC and CVD at the pathophysiological level, including chronic inflammation, metabolic abnormalities, hormonal dysregulation and neuroendocrine system activation. This review summarizes the potential interactions between BC and CVD, the associated cardiotoxicity induced by cancer therapies, and the application of relevant biomarkers in diagnosis and risk assessment, with the aim of providing insights and reference for the comprehensive management of patients with coexisting BC and CVD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.